ライフサイエンスコーパス: interleukin-2

1 d with impaired glycolysis and signaling via interleukin 2.

2 f both the magnitude of the TCR stimulus and Interleukin 2.

3 le by exogenous PD-1 blockade or addition of interleukin 2.

4 modified vaccinia Ankara expressing MUC1 and interleukin 2.

5 cells, by enhancing their responsiveness to interleukin-2.

6 ecrosis factor-alpha, and to a lesser extent interleukin-2.

7 regulate CD69 surface expression and secrete interleukin-2.

8 liferation in vitro that could be rescued by interleukin-2.

9 Subcutaneous interleukin 2 (1.5 million IU/d) was administered during

10 ; and T-cell cytokines interferon gamma, and interleukin 2, 10, and 17.

11 eased, were interleukin-4 (18.0 [6.0-54.2]), interleukin-2 (11.8 [4.3-32.2]), angiopoietin-2 (6.4 [1.

12 or the synthesis of N-(4-(18)F-fluorobenzoyl)interleukin-2 ((18)F-FB-IL2) and the in vitro and in viv

13 which include interferon alpha and gamma and interleukin 2, 2R, 6, 7, 12, 15, 17, and 18, across diff

14 forming cells (SFCs) of interferon gamma and interleukin 2, 4, 5, and 6 were counted by means of enzy

15 between the 2 groups for interferon gamma or interleukin 2, 4, or 5 (all P > .05).

16 g gamma chain-containing cytokines including interleukins 2, 4, 7, 9, 15, and 21.

17 ce was reported had higher concentrations of interleukin 2, 6, and 10, interferon gamma, tumor necros

18 of cytokines, including interferon-gamma and interleukins 2, 6, and 10 (IL-2, IL-6, and IL-10).

19 us infusion of autologous TILs and high-dose interleukin-2 [720 000 IU/kg] every 8 h).

20 d CD4(+) effector T cells (Teffs) to produce interleukin-2, a key survival factor for Tregs.

21 -type cells and bypassed the requirement for interleukin-2 administration to sustain in vivo activity

22 Interleukin 2 and IL-15 are two closely related cytokine

23 defects in allogeneic T-cell proliferation, interleukin 2 and interferon gamma (IFN-gamma) productio

24 Infection decreased interleukin 2 and interferon gamma production as well as

25 CCL2, CCL4, CCL13, CCL17, CXCL8, CXCL10; and interleukin 2 and interferon gamma than children who sur

26 nefit from immunotherapies such as high-dose interleukin 2 and ipilimumab, which, by contrast with BR

27 evelopment of CD4(+) T cells that coproduced interleukin 2 and tumor necrosis factor alpha and were a

28 coproteins form supramolecular clusters with interleukin-2 and -15 receptors in lipid rafts of T cell

29 n T cells (T-bet) expression and recovery of interleukin-2 and interferon-gamma production and cytoly

30 ecreased secretion of targeted genes such as interleukin-2 and interferon-gamma.

31 po crystal structure; iii) visualisations of interleukin-2 and its homologues highlight conserved poc

32 od-stage specific CD4(+) T cells coproducing interleukin-2 and tumor necrosis factor alpha (P = .003)

33 sus controls) and lower levels of binding to interleukins 2 and 10 core promoter regions of the trans

34 interferon-gamma/tumor necrosis factor-alpha/interleukin-2), and proliferation-related markers (CD119

35 d the expression of T-bet, interferon gamma, interleukin 2, and the antiapoptotic molecule Bcl-2, whe

36 cterized for expression of interferon-gamma, interleukin 2, and tumor necrosis factor alpha and surfa

37 f CD4(+) T cells for detection of IFN-gamma, interleukin 2, and tumor necrosis factor alpha was perfo

38 culating levels of type 1 (interferon gamma, interleukin 2, and tumor necrosis factor alpha) and type

39 in vitro T cell expansion in the presence of interleukin-2, and ex vivo staining with HCV peptide-loa

40 ing protein and the induction of CD25, CD69, interleukin-2, and gamma-interferon.

41 the immunotherapeutic cytokines interferon, interleukin-2, and interleukin-4.

42 medically relevant proteins--beta-lactamase, interleukin-2, and RNase H--even in the absence of any l

43 Interferon-gamma, interleukin-2, and tumor necrosis factor alpha (TNF-alph

44 ed intracellular levels of interferon gamma, interleukin-2, and tumor necrosis factor alpha in HBV-sp

45 Sustained production of IFN-gamma, interleukin-2, and tumor necrosis factor alpha was elici

46 Anti-interleukin-2 (anti-IL2) antibody has been covalently im

47 lls produced tumor necrosis factor alpha and interleukin 2 at the intrahepatic level significantly mo

48 ascular endothelial growth factor A (VEGFA), interleukin-2, bone morphogenetic protein-10, VEGFC, and

49 ents T-cell-receptor-dependent production of interleukin 2 by 34-fold.

50 ation and production of interferon-gamma and interleukin-2 by intrahepatic and peripheral T cells fro

51 Measurements of model cytokine interleukin-2 concentrations from <20 fM to >200 pM were

52 cell activation assessed by CD69 expression, interleukin-2 expression, and CD25 levels.

53 enhanced CD25 and CD69 expression, increased interleukin-2 expression, and improved proliferation of

54 EDA-fibronectin (EDA-Fn), when conjugated to interleukin-2 (F8-IL2) can effectively inhibit the growt

55 t the first use to our knowledge of low-dose interleukin 2 for treating severe AA by promoting the re

56 en twice-daily intraperitoneal injections of interleukin-2 for 10 days.

57 Using this screen, we identified interleukin-2 gamma receptor (IL2Rgamma) as a critical g

58 l killer (NK)-cell differentiation defect in interleukin-2 gamma-chain receptor (IL2RG)/JAK3 severe c

59 Administration of high-dose interleukin-2 (HDIL-2) has durable antitumor effects in

60 (1,300 peptides) using gamma interferon and interleukin-2 (IFN-gamma/IL-2) FluoroSpot analysis.

61 responses were screened by gamma interferon/interleukin-2 (IFN-gamma/IL-2) FluoroSpot using autologo

62 of T-helper type 1 intracellular cytokines (interleukin 2, IFN-gamma, and tumor necrosis factor alph

63 ting of dacarbazine, cisplatin, vinblastine, interleukin-2, IFN alfa-2b (IFN-alpha-2b) and granulocyt

64 equencies of interferon gamma (IFN-gamma(+))/interleukin 2 (IL-2(+))/tumor necrosis factor alpha (TNF

65 of regulatory T cells (Treg cells) requires interleukin 2 (IL-2) and agonist T cell antigen receptor

66 unique transcriptional program and produced interleukin 2 (IL-2) and IL-10.

67 ria monocytogenes epitope, elicited distinct interleukin 2 (IL-2) and phosphorylated kinase Erk respo

68 er levels of interferon gamma (IFN-gamma) or interleukin 2 (IL-2) ELISpot responses compared with eac

69 Interleukin 2 (IL-2) promotes Foxp3(+) regulatory T (Tre

70 e introduction of a targeted mutation in the interleukin 2 (IL-2) receptor common gamma chain (IL2rg(

71 to agonist-driven TCR signals combined with interleukin 2 (IL-2) receptor signalling.

72 tumor necrosis factor alpha (TNF-alpha), and interleukin 2 (IL-2) secretion by CD8(+) T cells.

73 ptor (TCR) but does not affect PMA-activated interleukin 2 (IL-2) secretion.

74 TRAF3 dampened interleukin 2 (IL-2) signaling by facilitating recruitme

75 Interleukin 2 (IL-2) signaling through the IL-2 receptor

76 CD8(+) T cells by inflammatory mediators and interleukin 2 (IL-2) via pathways dependent on the metab

77 ncludes simian immunodeficiency virus (SIV), interleukin 2 (IL-2), and IL-15 DNAs, recombinant modifi

78 d secretion of interferon gamma (IFN-gamma), interleukin 2 (IL-2), and tumor necrosis factor alpha (T

79 Interleukin 2 (IL-2), IL-10 and transforming growth fact

80 rted their regulatory function by inhibiting interleukin 2 (IL-2)-dependent de novo differentiation o

81 GM-CSF is strongly induced by interleukin 2 (IL-2).

82 enes or altered ability to sense and consume interleukin 2 (IL-2).

83 (TH1 cells) exposed to low concentrations of interleukin 2 (IL-2).

84 NFAT-dependent promoters of either RCAN1 or interleukin 2 (IL-2).

85 d levels of interferon gamma (IFN-gamma) and interleukin 2 (IL-2; markers of VZV-specific cell-mediat

86 asymmetric partitioning of the receptor for interleukin 2 (IL-2Ralpha) during mitosis.

87 compared to CD8(+) T cells) that coexpressed interleukin-2 (IL-2) (66.4%) and/or tumor necrosis facto

88 tumor necrosis factor alpha (TNF-alpha), and interleukin-2 (IL-2) (P < 0.001) and splenic and lung CD

89 nfiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted pati

90 Here we show that interleukin-2 (IL-2) administration impaired influenza-s

91 Administration of low-dose interleukin-2 (IL-2) alone or combined with rapamycin (R

92 maintained CD25 expression and responded to interleukin-2 (IL-2) and CD27, which together programmed

93 ne function via changes to cytokines such as interleukin-2 (IL-2) and IL-10 and may predict disease p

94 We compared the ability of interleukin-2 (IL-2) and IL-15 to sustain human NK-cell

95 to selectively up-regulate the production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) an

96 -associated CXCR3/CCR5 and TNFalpha/IFNgamma/interleukin-2 (IL-2) and less TH2-associated CCR3/CCR4,

97 of antigen-specific Treg cells induced with interleukin-2 (IL-2) and transforming growth factor beta

98 vation from latency but inhibits CD3-induced interleukin-2 (IL-2) and tumor necrosis factor alpha (TN

99 roliferative capacity and ability to secrete interleukin-2 (IL-2) and tumor necrosis factor alpha (TN

100 ccination induced an increased expression of interleukin-2 (IL-2) by Gp120-specific CD4(+) T cells in

101 Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice e

102 tumor necrosis factor-alpha (TNF-alpha) and interleukin-2 (IL-2) cytokines with a rate of approximat

103 e data obtained with overlapping peptides in interleukin-2 (IL-2) enzyme-linked immunosorbent spot (E

104 ay, normally activated by cytokines from the interleukin-2 (IL-2) family to promote cell proliferatio

105 consisting of the immunostimulatory cytokine interleukin-2 (IL-2) genetically fused to an antibody sp

106 Interleukin-2 (IL-2) has an essential role in the expans

107 ifferentiation and in particular the role of interleukin-2 (IL-2) in promoting or inhibiting Th diffe

108 glucose metabolism is sufficient to support interleukin-2 (IL-2) induction.

109 Low-dose interleukin-2 (IL-2) inhibited unwanted immune responses

110 Interleukin-2 (IL-2) is a critical cytokine for the home

111 Interleukin-2 (IL-2) is a cytokine that has multiple inf

112 Interleukin-2 (IL-2) is a fundamental cytokine that cont

113 The immunostimulatory cytokine interleukin-2 (IL-2) is a growth factor for a wide range

114 Interleukin-2 (IL-2) is a pleiotropic cytokine produced

115 Interleukin-2 (IL-2) is a pleiotropic cytokine that regu

116 Interleukin-2 (IL-2) is a potent cytokine with roles in

117 tigen on ACT cells (Thy1.1) or an engineered interleukin-2 (IL-2) molecule on an Fc framework as targ

118 ly, antibody-mediated blockade of IFN-gamma, interleukin-2 (IL-2) or interleukin-15 receptor beta (IL

119 lpha (TNF-alpha), gamma IFN (IFN-gamma), and interleukin-2 (IL-2) production.

120 tor of activated T cells (NFAT) and suppress interleukin-2 (IL-2) production.

121 hrough the T-cell antigen receptor (TCR) and interleukin-2 (IL-2) provide major inputs for mTORC1 act

122 ex virus 1 (HSV-1) constitutively expressing interleukin-2 (IL-2) provokes central nervous system (CN

123 Treg cells led to reduced expression of the interleukin-2 (IL-2) receptor alpha subunit CD25, accumu

124 udies now highlight deficiencies in both the interleukin-2 (IL-2) receptor and its downstream signali

125 ymocyte globulin (r-ATG), alemtuzumab, or an interleukin-2 (IL-2) receptor blocker and were discharge

126 t of human AML cells in NOD-SCID gamma (with interleukin-2 (IL-2) receptor gamma chain deficiency) mi

127 ody, Toll-like receptor 7 (TLR7) agonist and interleukin-2 (IL-2) reduced T cell apoptosis but did no

128 Interleukin-2 (IL-2) regulates lymphocyte function by si

129 multiple sclerosis (RRMS) because of altered interleukin-2 (IL-2) secretion and IL-2 receptor (IL-2R)

130 T cells inhibited T cell receptor (TCR) and interleukin-2 (IL-2) signaling and upregulated PD-1, lea

131 tion of kynurenine correlates with defective interleukin-2 (IL-2) signaling in memory CD4 T cells fro

132 Given the importance of interleukin-2 (IL-2) signaling in the generation and fun

133 iation of pathogenic Trm cells revealed that interleukin-2 (IL-2) signaling was required for residenc

134 ase 1 studies identified a low daily dose of interleukin-2 (IL-2) that was well tolerated, did not ex

135 cal models and patients undergoing high-dose interleukin-2 (IL-2) therapy.

136 ering therapeutic doses of recombinant human interleukin-2 (IL-2) to AGMs, we show here that this mec

137 Interleukin-2 (IL-2) was originally discovered as a grow

138 tumor necrosis factor alpha (TNF-alpha), and interleukin-2 (IL-2) were detected in splenocytes.

139 frequency of interferon-gamma (IFN-gamma)(+) interleukin-2 (IL-2)(-) CD8(+) T cells (r = -0.6, P = 0.

140 Therefore, high doses of interleukin-2 (IL-2), a conventional cytokine for metast

141 py with cisplatin, vinblastine, dacarbazine, interleukin-2 (IL-2), and interferon alfa as part of a c

142 with reduced expression of interferon-gamma, interleukin-2 (IL-2), and soluble IL-2Ralpha, but did no

143 d through the in vitro addition of exogenous interleukin-2 (IL-2), and the in vivo blockade of the re

144 PD-1 blockade strongly augmented IFN-gamma, interleukin-2 (IL-2), and TNF-alpha production.

145 ly, and very few cells produce IFN-gamma and interleukin-2 (IL-2), compared with transgenic T cells i

146 OT-II T cells to proliferate and to secrete interleukin-2 (IL-2), demonstrating a functional consequ

147 unctional and able to simultaneously produce interleukin-2 (IL-2), gamma interferon (IFN-gamma), and

148 re elevated frequencies of T cells producing interleukin-2 (IL-2), IL-10, and IL-17 and decreased IL-

149 Treatment with cytokine interleukin-2 (IL-2), IL-4, IL-7, or IL-15 renders CD4(+

150 e show that the T cell homeostatic cytokines interleukin-2 (IL-2), IL-7, and IL-15 can induce CD4 dow

151 4+ T cells was induced in vitro by anti-CD3, interleukin-2 (IL-2), IL-7, or IL-15 but not by Toll-lik

152 confer susceptibility to type 1 diabetes at interleukin-2 (IL-2), IL2/4q27 (rs2069763) and renalase,

153 at distinguished LTBI from controls included interleukin-2 (IL-2), monocyte chemotactic protein 2 (MC

154 ma, tumor necrosis factor alpha (TNF-alpha), interleukin-2 (IL-2), perforin, and CD107a.

155 the activation markers CD40 ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-a

156 Interferon-alpha (IFN-alpha), interleukin-2 (IL-2), tumor necrosis factor-alpha (TNFal

157 PB CD4(+) T cells produced predominantly interleukin-2 (IL-2), whereas CD4(+) and CD8(+) T-cell s

158 h factor-beta (TGF-beta)-activated Smad3 and interleukin-2 (IL-2)-activated Stat5 facilitated Tet1 an

159 These data identify the interleukin-2 (IL-2)-mTORc1 axis as a critical orchestra

160 e investigated the regulation of the size of interleukin-2 (IL-2)-producing CD4(+) T cell (IL-2p) poo

161 We found that aspects of the interleukin-2 (IL-2)-sensitive effector gene program in

162 (TCR) and pro-inflammatory cytokines such as interleukin-2 (IL-2).

163 ining magnetite and the T-cell growth factor interleukin-2 (IL-2).

164 associated with diminished DC expression of interleukin-2 (IL-2).

165 with DNA simian immunodeficiency virus (SIV)/interleukin-2 (IL-2)/IL-15, SIV Gag/Pol/Env recombinant

166 n FOXP3(hi), CD127(lo) Tregs), expresses the interleukin-2 (IL-2)/STAT5 pathway and cell-cycle commit

167 tumor necrosis factor alpha [TNF-alpha], and interleukin 2 [IL-2]) and cytolytic molecules (granzyme

168 or [gammadelta-TCR]) and cytokines examined (interleukin 2 [IL-2], IL-4, IL-10, IL-17A, and gamma int

169 revealed a defect in the expression of CD25 (interleukin-2 [IL-2] receptor alpha chain) on Ad5-elicit

170 tumor necrosis factor alpha [TNF-alpha], and interleukin-2 [IL-2]) and type 17 (IL-17A and/or IL-17F)

171 tumor necrosis factor alpha [TNF-alpha], and interleukin-2 [IL-2]), and the cytolytic mediator granzy

172 ma and/or tumor necrosis factor [TNF] and/or interleukin-2 [IL-2])-producing CD4(+) and CD8(+) T cell

173 secretion of candidate cytokines/chemokines (interleukin-2 [IL-2], IL-6, IL-10, MIP-1alpha, and RANTE

174 yze T-cell activation markers (CD107, CD154, interleukin-2 [IL-2], tumor necrosis factor [TNF], and I

175 PREX1-Rac1-signaling pathway that stabilizes interleukin-2(IL-2), IL-4, and IL-10 messenger RNA (mRNA

176 The pleiotropic cytokine interleukin 2 (IL2) disrupts the blood-brain barrier and

177 Interleukin-2 (IL2) binds with high affinity to the IL2

178 nes, including IFNgamma, interleukin 12, and interleukin 2 in plasma of Pip4k2c(-/-) mice.

179 SCM cells had increased abilities to secrete interleukin-2 in response to viral antigen, while secret

180 o support the role of CD28 costimulation and interleukin-2 in Treg homeostasis.

181 In T cells, the Tec family kinase, interleukin-2-induced tyrosine kinase (ITK), phosphoryla

182 hibitor of both Bruton's tyrosine kinase and interleukin-2 inducible kinase (ITK), has been used to t

183 The absence of the Tec family kinase Interleukin-2 inducible T cell kinase (Itk) results in T

184 Itk (interleukin-2 inducible T cell kinase) is a non-receptor

185 Interleukin-2 inducible T-cell kinase (ITK), a member of

186 Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing the

187 Interleukin-2-inducible T-cell kinase (ITK) and resting

188 Interleukin-2-inducible T-cell kinase (Itk) is a member

189 Here we demonstrate that interleukin-2-inducible T-cell kinase (Itk) signaling in

190 hibits Bruton tyrosine kinase in B cells and interleukin-2-inducible T-cell kinase in T cells.

191 alogue obtained was effective at suppressing interleukin-2 induction in mice.

192 Tato et al. demonstrate that high amounts of interleukin-2 inhibit production of this critical T effe

193 The use of immunotherapy with interleukin 2, interferon gamma, and interleukin 7 as an

194 by intracellular staining for the cytokines interleukin 2, interferon gamma, and tumor necrosis fact

195 Expression of proinflammatory cytokines interleukin 2, interferon gamma, tumor necrosis factor a

196 week 24 with appearance of HIV gag-specific interleukin 2, interferon-gamma, and CD107a responses in

197 have been conjugated via this method include interleukin-2, interferon-alpha, ubiquitin, antibodies a

198 f proinflammatory and profibrotic cytokines (interleukin-2, interferon-gamma, and interleukin-17) whe

199 m antigen, and interferon gamma (IFN-gamma), interleukin 2, interleukin 10, and tumor necrosis factor

200 heir HLA-matched siblings in the presence of interleukin 2, interleukin 15, and rapamycin.

201 vels of interferon gamma, interleukin 1beta, interleukin 2, interleukin 6, and interleukin 13 were si

202 terferon gamma (IFNgamma), interleukin1beta, interleukin 2, interleukin 6, interleukin 10 (IL-10), an

203 They secrete interferon-gamma, interleukin-2, interleukin-10, and tumor necrosis factor

204 gnificantly higher admission serum levels of interleukin-2, interleukin-12, interferon-gamma, and tum

205 Level of interleukin-1beta, interleukin-2, interleukin-4, interleukin-5, interleukin

206 active protein, tumor necrosis factor-alpha, interleukin-2, interleukin-6, and interleukin-8) have be

207 at this infection leads to the production of interleukin-2, interleukin-6, and transforming growth fa

208 The cytokines interleukin-2, interleukin-7, and interleukin-15 increas

209 lysis further implicates IFNgamma, IFNalpha, interleukin-2, interleukin-7, CTLA-4 (cytotoxic T-lympho

210 ependent type I interferon signaling and the interleukin-2/interleukin-2 receptor alpha pathway for t

211 ith Leishmania-specific interferon gamma and interleukin 2 levels, and negatively with Leishmania ski

212 Interleukin-2-mediated STAT5 phosphorylation in patients

213 explored 2 means to increase Tregs in cGVHD: interleukin-2/monoclonal antibody (IL-2/mAb) complexes a

214 h and without preactivation by interleukins (interleukin-2 or interleukin-6), was evaluated in the pr

215 LPTs were activated with interleukin-2 or via CD3, CD2, and CD28 signaling, and c

216 lowing cGVHD therapies including prednisone, interleukin-2, or extracorporeal photophoresis.

217 m the fMLP signal, while only 15.2 or 22.2% (interleukin-2-or interleukin-6-activated) of preactivate

218 Inverse correlation with high-dose interleukin-2 outcomes was also observed for the CLEAR s

219 d NKp30/MAPK/IL-12 (interleukin-12) or IL-2 (interleukin-2) pathway was susceptible to NK lysis.

220 tumor necrosis factor-alpha [TNF-alpha] and interleukin-2 pathways), and research on intravitreal bi

221 oly(I . C)LC induced potent multifunctional (interleukin 2-positive [IL-2(+)], tumor necrosis factor

222 n levels of interferon gamma (IFN-gamma) and interleukin 2 produced by T-helper 1 cells when comparin

223 timulate P2X4 and P2X7 receptors that elicit interleukin 2 production and T cell proliferation.

224 interferon, tumor necrosis factor alpha, and interleukin-2 production and CD107(a/b) cytotoxic degran

225 activated T-cells (NFAT) transcription, and interleukin-2 production in Jurkat or primary T-cells.

226 Interleukin-2 production in mitogen-stimulated CD3(+) T

227 imilarly, we found that lenalidomide-induced interleukin-2 production in T cells is due to depletion

228 Old observations, such as the decreased interleukin-2 production, are better understood with our

229 e normal T cell receptor (TCR) signaling and interleukin-2 production, WASHout T cells demonstrate si

230 0, and mitogen-activated protein kinase, and interleukin-2 production.

231 the inhibitory effects of glucocorticoids on interleukin-2 production.

232 k alleles, where ORMDL3 negatively regulated interleukin-2 production.

233 Treg activity, by inducing the production of interleukin 2 proinflammatory cytokines in these cells.

234 , or a combination (29/37), elevated soluble interleukin 2 receptor (20/21), and elevated VEGF (16/20

235 genitors by augmenting responsiveness of the interleukin 2 receptor (IL-2R) and transcription factor

236 ells), which have abundant expression of the interleukin 2 receptor (IL-2R), are reliant on IL-2 prod

237 To compare the value of soluble interleukin 2 receptor (sIL-2R) with ACE as diagnostic b

238 te (gamma interferon [IFN-gamma] and soluble interleukin 2 receptor alpha [sIL-2Ralpha]) and adaptive

239 le tumor necrosis factor receptor 2, soluble interleukin 2 receptor alpha, soluble gp130, soluble CD2

240 tandard immunosuppression with Thymoglobulin/interleukin 2 receptor blocker and mycophenolate mofetil

241 odeficiency (SCID-X1) caused by mutations in interleukin 2 receptor gamma (IL2RG) gene threatens the

242 ransplantation into immunodeficient NOD/SCID/interleukin 2 receptor gamma chain null mice.

243 2Mit80, an interval that includes Il2ra (for interleukin 2 receptor, alpha chain), a gene that is kno

244 vel was independent of that from circulating interleukin-2 receptor (IL-2R) or IL-8 levels.

245 The soluble interleukin-2 receptor (sIL-2R, sIL2R, sTAC, sCD25) is a

246 f a model PM protein, the alpha chain of the interleukin-2 receptor (Tac).

247 tosis reporter system using a chimera of the interleukin-2 receptor alpha (previously referred to as

248 n, soluble interleukin-1 receptor I, soluble interleukin-2 receptor alpha, and tumor necrosis factor

249 e clearance was also similar between groups (interleukin-2 receptor antagonist group 56 +/- 20 mL/min

250 e low and similar between groups (10% in the interleukin-2 receptor antagonist group vs 6% in the RAT

251 The impact of induction (thymoglobulin, interleukin-2 receptor antagonists [IL-2RA], or alemtuzu

252 antithymocyte globulin (RATG) compared with interleukin-2 receptor antagonists in a racially diverse

253 tandard induction immunosuppression was with interleukin-2 receptor antagonists, and antithymocyte gl

254 A total of 200 patients (n = 98 in the interleukin-2 receptor antagonists, and n = 102 in the R

255 isk of BPAR compared with induction with the interleukin-2 receptor antibodies (IL-2RAs): basiliximab

256 lso distinguished patients who received anti-interleukin-2 receptor antibodies from those who receive

257 phenolate mofetil, corticosteroids, and anti-interleukin-2 receptor antibody induction, results in im

258 phenolate mofetil, corticosteroids, and anti-interleukin-2 receptor antibody induction, was associate

259 l as either rabbit antithymocyte globulin or interleukin-2 receptor antibody induction.

260 tely by increased immunosuppression and anti-interleukin-2 receptor antibody.

261 tion treatments (alemtuzumab, thymoglobulin, interleukin-2 receptor blockers, and no induction) given

262 is due to mutations in the gene encoding the Interleukin-2 receptor gamma chain (IL-2Rgamma), leading

263 of iCD8alpha cells depends on expression of interleukin-2 receptor gamma chain (IL-2Rgammac), IL-15,

264 rus-based gamma-retrovirus vector expressing interleukin-2 receptor gamma-chain (gammac) complementar

265 r-like effector nucleases (TALENs) to target interleukin-2 receptor subunit gamma (IL2RG) in pronucle

266 ody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 sign

267 CD25, the alpha chain of the interleukin-2 receptor, is expressed in activated T cell

268 1beta, and interleukin-7) as well as soluble interleukin-2 receptor-alpha were significantly elevated

269 ry group, whereas interleukin-1beta, soluble interleukin-2 receptor-alpha, interleukin-4, interleukin

270 , rabbit antithymocyte globulin (r-ATG), and interleukin-2 receptor-antagonist.

271 IL-2 signals via interleukin-2 receptor-beta (IL-2Rbeta):IL-2Rgamma heter

272 NOD-scid interleukin-2 receptor-negative (IL-2Rgamma(-/-)) (NSG)-

273 FR, VEGFR, PDGFR, NGFR and IGF1R, as well as interleukin-2 receptor.

274 Although the clinical benefit of interleukin-2-receptor antibody (IL-2RAb) induction in r

275 eron gamma, tumor necrosis factor alpha, and interleukin 2) responses were discordant in frequency an

276 and CD8+ T cells and a higher proportion of interleukin 2-secreting cells (P = .01 and P = .002, res

277 and enhanced TCR-induced CD69 upregulation, interleukin-2 secretion, and proliferation to promote vi

278 Abnormalities in interleukin-2 signaling have been implicated in the path

279 Specifically, interleukin-2 signaling pathway mutations, including act

280 of the interleukin-2 receptor) and modulates interleukin-2 signaling.

281 alpha (tissue necrosis factor-alpha) and IL (interleukin)-2 soluble receptors and NT-proBNP (N-Termin

282 BTLA(-) T cells but more IFN-gamma, TNF, and interleukin-2 than the highly dysfunctional subset expre

283 y a rapid response team for complications of interleukin-2 therapeutic infusions were subsequently ex

284 ll differentiation by limiting the access of interleukin 2 to CD4(+) T cells, thereby enhancing Tfh c

285 co-operates with growth factor TGF-beta and interleukin-2 to activate Tet-mediated DNA demethylation

286 tumor necrosis factor alpha (TNF-alpha), and interleukin 2 together, compared with delayed vaccinatio

287 s with Childhood Acute Myeloid Leukemia with Interleukin-2 trials (age, 1-60 years).

288 4 cytokines evaluated (ie, interferon gamma, interleukin 2, tumor necrosis factor alpha, and granzyme

289 the functional diversity (ie, CD107, CD154, interleukin 2, tumor necrosis factor, and interferon gam

290 vely studying five effector functions (i.e., interleukin-2, tumor necrosis factor-alpha, interferon-g

291 g aspartate-directed protease 3 (caspase-3), interleukin-2, tumor necrosis factor-related apoptosis-i

292 rophage colony-stimulating factor) and IL-2 (interleukin-2), two pleiotropic cytokines of the mammali

293 Exposure to interleukin 2 was also sufficient to induce lytic granul

294 ng on the well-characterized T-cell cytokine interleukin-2, we show how cytokine secretion and compet

295 eron gamma, tumor necrosis factor alpha, and interleukin 2 were quantified using intracellular cytoki

296 n gamma, tumor necrosis factor alpha, and/or interleukin 2, were present at the peak response.

297 lpha (TNF-alpha) but not interferon gamma or interleukin 2 which had a differentiated effector phenot

298 erative capacity and produced cytokines like interleukin-2, while revealing similar suppressive poten

299 or-antigen-targeting antibody, a recombinant interleukin-2 with an extended half-life, anti-PD-1 and

300 2 hours and then cultured in the presence of interleukin-2 with vehicle control or the SSRI (10(-6) m